| http://www.w3.org/ns/prov#value | - Such breakthrough treatments and their stratospheric price tags have absolutely caused insurers to reconsider covering high-priced hepatitis, diabetes and other treatments, said Sumit Dutta, chief medical officer of Catamaran, the fourth-biggest U.S. pharmacy benefit manager, or PBM.You can not manage exclusively by the techniques PBMs have used in the past, Dutta said by telephone.
|
